Emerging evidence on the role of breast microbiota on the development of breast cancer in high-risk patients

被引:1
|
作者
Actis, Silvia [1 ]
Cazzaniga, Massimiliano [2 ]
Bounous, Valentina Elisabetta [1 ]
D'Alonzo, Marta [1 ]
Rosso, Roberta [1 ]
Accomasso, Francesca [1 ]
Minella, Carola [1 ]
Biglia, Nicoletta [1 ]
机构
[1] Univ Turin, Mauriziano Umberto Hosp 1, Dept Surg Sci, Gynecol & Obstet Unit, I-10128 Turin, Italy
[2] Velleja Res, Sci & Res Dept, I-20125 Milan, Italy
关键词
HUMAN-PAPILLOMAVIRUS INFECTION; DOUBLE-STRAND BREAKS; BETA-GLUCURONIDASE; GUT BACTERIA; DNA-DAMAGE; IN-VIVO; BRCA1; P53; MUTATION; REPAIR;
D O I
10.1093/carcin/bgad071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer is a multi-factorial disease, and the etiology of breast cancer (BC) is due to a combination of both genetic and environmental factors. Breast tissue shows a unique microbiota, Proteobacteria and Firmicutes are the most abundant bacteria in breast tissue, and several studies have shown that the microbiota of healthy breast differs from that of BC. Breast microbiota appears to be correlated with different characteristics of the tumor, and prognostic clinicopathologic features. It also appears that there are subtle differences between the microbial profiles of the healthy control and high-risk patients. Genetic predisposition is an extremely important risk factor for BC. BRCA1/2 germline mutations and Li-Fraumeni syndrome are DNA repair deficiency syndromes inherited as autosomal dominant characters that substantially increase the risk of BC. These syndromes exhibit incomplete penetrance of BC expression in carrier subjects. The action of breast microbiota on carcinogenesis might explain why women with a mutation develop cancer and others do not. Among the potential biological pathways through which the breast microbiota may affect tumorigenesis, the most relevant appear to be DNA damage caused by colibactin and other bacterial-derived genotoxins, beta-glucuronidase-mediated estrogen deconjugation and reactivation, and HPV-mediated cancer susceptibility. In conclusion, in patients with a genetic predisposition, an unfavorable breast microbiota may be co-responsible for the onset of BC. Prospectively, the ability to modulate the microbiota may have an impact on disease onset and progression in patients at high risk for BC. The presence of breast microbiota has been known for several years. The etiology of breast cancer (BC) is due to a combination of both genetic and environmental factors. BRCA1/2 germline mutations and Li-Fraumeni syndrome are inherited as an autosomal dominant character but do not exhibit complete penetrance in carrier subjects. The local microbiota of the breast may influence breast tumor incidence and prognosis. Patients with genetically inherited impaired DNA repair may be more susceptible to bacterially induced DNA damage. This review aims to analyse the evidence that may allow an understanding of whether and how the penetrance of genetic predisposition may be influenced by breast microbiota. Graphical Abstract
引用
收藏
页码:718 / 725
页数:8
相关论文
共 50 条
  • [31] Breast MRI as an Adjunct to Mammography for Breast Cancer Screening in High-Risk Patients: Retrospective Review
    Rakow-Penner, R.
    Ojeda-Fournier, H.
    BREAST DISEASES, 2016, 27 (01): : 41 - 42
  • [32] Breast MRI as an Adjunct to Mammography for Breast Cancer Screening in High-Risk Patients: Retrospective Review
    Raikhlin, Antony
    Curpen, Belinda
    Warner, Ellen
    Betel, Carrie
    Wright, Barbara
    Jong, Roberta
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2015, 204 (04) : 889 - 897
  • [33] ABC OF BREAST DISEASES - CARCINOMA IN-SITU AND PATIENTS AT HIGH-RISK OF BREAST-CANCER
    PAGE, DL
    STEEL, CM
    DIXON, JM
    BRITISH MEDICAL JOURNAL, 1995, 310 (6971): : 39 - 42
  • [34] End of high-dose chemotherapy for high-risk breast cancer patients?
    Tuma, Rabiya S.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (09) : 618 - U3
  • [35] High-dose sequential chemotherapy in patients with high-risk breast cancer
    Sabbatini, R
    Frassineti, L
    Depenni, R
    BONE MARROW TRANSPLANTATION, 2001, 27 : S119 - S119
  • [36] Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer
    Lonning, P. E.
    Clausen, C.
    Blix, E. S.
    Lundgren, S.
    Vagstad, G.
    Espelid, H.
    Gilje, B.
    Janssen, E. A.
    Geisler, J.
    Aas, T.
    Aase, H.
    Knappskog, S.
    Eikesdal, H. P.
    ANNALS OF ONCOLOGY, 2019, 30 : 59 - +
  • [37] Intensified Surveillance for Early Detection of Breast Cancer in High-Risk Patients
    Bick, Ulrich
    BREAST CARE, 2015, 10 (01) : 13 - 20
  • [38] ETC-Regime: Help for High-risk breast cancer patients
    Moebus, Volker
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2012, 72 (05) : 367 - 369
  • [39] Prediction of responsiveness to adjuvant anthracyclines in high-risk breast cancer patients
    Brunner, N.
    Ejlertsen, B.
    Jensen, M.
    Nielsen, K. V.
    Balslev, E.
    Rasmussen, B. B.
    Willemoe, G. L.
    Hertel, P. B.
    Knoop, A.
    Mouridsen, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Is Baseline Bone Imaging in High-Risk Breast Cancer Patients Justified?
    Ampil, Federico L.
    Li, Benjamin D. L.
    Burton, Gary V.
    Kim, Roger H.
    Baluna, Roxana G.
    Chu, Quyen
    BREAST JOURNAL, 2012, 18 (06): : 639 - 640